Physician profile
Virginia Chen
NPI 1811085319
$3,019.20
in general payments reported to CMS, 2019-2025
16 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,393 · 2020: $368 · 2022: $131 · 2023: $344 · 2024: $419 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $742.84 | 2019-2025 | Nucala |
| Abbvie INC. | $366.95 | 2019 | |
| Sun Pharmaceutical Industries INC. | $335.82 | 2019-2023 | Odomzo |
| Astrazeneca Pharmaceuticals Lp | $243.73 | 2019-2024 | Airsupra |
| Mallinckrodt Enterprises LLC | $145.91 | 2019 | |
| Aclaris Therapeutics, INC. | $137.50 | 2019 | |
| Epi Health, LLC | $131.09 | 2022 | |
| Pfizer INC. | $129.07 | 2019 | |
| Optinose US, INC. | $125.00 | 2024 | |
| Mylan Specialty L.P. | $125.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $123.34 | 2020 | |
| Mallinckrodt Hospital Products INC. | $119.39 | 2020 | |
| Celgene Corporation | $115.91 | 2019 | |
| Insmed, INC. | $114.17 | 2025 | Brinsupri |
| Intra-Sana Laboratories | $50.00 | 2024 | Reltone 200 Mg, Reltone 400 Mg |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.